Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery

Jin Sun Cho, Jae Kwang Shim, Sara Soh, Min Kyung Kim, Younglan Kwak

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Acute kidney injury (AKI) following cardiac surgery is closely interrelated with hemodynamic instability and sympathetic activity, and adversely influences prognosis. Here, we investigated in a randomized placebo-controlled trial whether dexmedetomidine, an α2 adrenoreceptor agonist, could prevent AKI after valvular heart surgery. Two hundred patients undergoing valvular heart surgery were randomly assigned to equal placebo or treatment groups. Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery. We then assessed the incidence of AKI during the first 48 postoperative hours, hemodynamic variables, and a composite of major morbidity end points. The incidence of AKI, based on Acute Kidney Injury Network criteria, was significantly lower in the treatment group compared with the control group (14 vs. 33%). The dexmedetomidine group exhibited a significantly lower incidence of a composite of major morbidity end points (21 vs. 38%) and a significantly shorter length of intensive care unit stay (3 [2, 3] days vs. 3 [2, 4] days) compared with the control group. Thus, perioperative infusion of dexmedetomidine effectively reduced both the incidence and severity of AKI, and improved outcome in patients undergoing valvular heart surgery without untoward hemodynamic side effects.

Original languageEnglish
Pages (from-to)693-700
Number of pages8
JournalKidney International
Volume89
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Dexmedetomidine
Acute Kidney Injury
Thoracic Surgery
Incidence
Hemodynamics
Placebos
Morbidity
Control Groups
Intensive Care Units
Anesthetics
Randomized Controlled Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Cho, Jin Sun ; Shim, Jae Kwang ; Soh, Sara ; Kim, Min Kyung ; Kwak, Younglan. / Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. In: Kidney International. 2016 ; Vol. 89, No. 3. pp. 693-700.
@article{7139a4d7ab4844559dce7d271a5903e2,
title = "Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery",
abstract = "Acute kidney injury (AKI) following cardiac surgery is closely interrelated with hemodynamic instability and sympathetic activity, and adversely influences prognosis. Here, we investigated in a randomized placebo-controlled trial whether dexmedetomidine, an α2 adrenoreceptor agonist, could prevent AKI after valvular heart surgery. Two hundred patients undergoing valvular heart surgery were randomly assigned to equal placebo or treatment groups. Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery. We then assessed the incidence of AKI during the first 48 postoperative hours, hemodynamic variables, and a composite of major morbidity end points. The incidence of AKI, based on Acute Kidney Injury Network criteria, was significantly lower in the treatment group compared with the control group (14 vs. 33{\%}). The dexmedetomidine group exhibited a significantly lower incidence of a composite of major morbidity end points (21 vs. 38{\%}) and a significantly shorter length of intensive care unit stay (3 [2, 3] days vs. 3 [2, 4] days) compared with the control group. Thus, perioperative infusion of dexmedetomidine effectively reduced both the incidence and severity of AKI, and improved outcome in patients undergoing valvular heart surgery without untoward hemodynamic side effects.",
author = "Cho, {Jin Sun} and Shim, {Jae Kwang} and Sara Soh and Kim, {Min Kyung} and Younglan Kwak",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/ki.2015.306",
language = "English",
volume = "89",
pages = "693--700",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. / Cho, Jin Sun; Shim, Jae Kwang; Soh, Sara; Kim, Min Kyung; Kwak, Younglan.

In: Kidney International, Vol. 89, No. 3, 01.03.2016, p. 693-700.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery

AU - Cho, Jin Sun

AU - Shim, Jae Kwang

AU - Soh, Sara

AU - Kim, Min Kyung

AU - Kwak, Younglan

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Acute kidney injury (AKI) following cardiac surgery is closely interrelated with hemodynamic instability and sympathetic activity, and adversely influences prognosis. Here, we investigated in a randomized placebo-controlled trial whether dexmedetomidine, an α2 adrenoreceptor agonist, could prevent AKI after valvular heart surgery. Two hundred patients undergoing valvular heart surgery were randomly assigned to equal placebo or treatment groups. Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery. We then assessed the incidence of AKI during the first 48 postoperative hours, hemodynamic variables, and a composite of major morbidity end points. The incidence of AKI, based on Acute Kidney Injury Network criteria, was significantly lower in the treatment group compared with the control group (14 vs. 33%). The dexmedetomidine group exhibited a significantly lower incidence of a composite of major morbidity end points (21 vs. 38%) and a significantly shorter length of intensive care unit stay (3 [2, 3] days vs. 3 [2, 4] days) compared with the control group. Thus, perioperative infusion of dexmedetomidine effectively reduced both the incidence and severity of AKI, and improved outcome in patients undergoing valvular heart surgery without untoward hemodynamic side effects.

AB - Acute kidney injury (AKI) following cardiac surgery is closely interrelated with hemodynamic instability and sympathetic activity, and adversely influences prognosis. Here, we investigated in a randomized placebo-controlled trial whether dexmedetomidine, an α2 adrenoreceptor agonist, could prevent AKI after valvular heart surgery. Two hundred patients undergoing valvular heart surgery were randomly assigned to equal placebo or treatment groups. Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continuing for 24 h after surgery. We then assessed the incidence of AKI during the first 48 postoperative hours, hemodynamic variables, and a composite of major morbidity end points. The incidence of AKI, based on Acute Kidney Injury Network criteria, was significantly lower in the treatment group compared with the control group (14 vs. 33%). The dexmedetomidine group exhibited a significantly lower incidence of a composite of major morbidity end points (21 vs. 38%) and a significantly shorter length of intensive care unit stay (3 [2, 3] days vs. 3 [2, 4] days) compared with the control group. Thus, perioperative infusion of dexmedetomidine effectively reduced both the incidence and severity of AKI, and improved outcome in patients undergoing valvular heart surgery without untoward hemodynamic side effects.

UR - http://www.scopus.com/inward/record.url?scp=84943303026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943303026&partnerID=8YFLogxK

U2 - 10.1038/ki.2015.306

DO - 10.1038/ki.2015.306

M3 - Article

VL - 89

SP - 693

EP - 700

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -